AbbVie (ABBV) on Monday announced positive results from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab in moderately to severely active Crohn's disease.
At Week 12, 55 percent of patients treated with risankizumab achieved clinical remission compared to 30 percent on placebo, while 44 percent achieved endoscopic response versus 14 percent on placebo.
The benefits were observed in both treatment-naïve and refractory patients. By Week 24, following induction and maintenance therapy, 67 percent of patients achieved clinical remission and 57% endoscopic response. The safety profile was consistent with previous studies, with no new safety signals identified.
ABBV is currently trading pre market at $229.51, down $2.52 or 1.09 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.